MODIFICATION
70 -- Intrinsic Bioprobes, Inc
- Notice Date
- 8/19/2011
- Notice Type
- Modification/Amendment
- Contracting Office
- 2920 Brandywine Road, Atlanta, GA 30341
- ZIP Code
- 30341
- Solicitation Number
- 01673
- Response Due
- 8/22/2011
- Archive Date
- 2/18/2012
- Point of Contact
- Name: Client Services, Title: Client Services, Phone: 877.933.3243, Fax: 703.422.7822
- E-Mail Address
-
Clientservices@fedbid.com;
- Small Business Set-Aside
- Total Small Business
- Description
- CANCELLATION NOTICE:Bids are being solicited under solicitation number 01673. This announcement constitutes the only solicitation; bids are being requested and a written solicitation will not be issued. The solicitation is issued as an invitation for bids (IFB), unless otherwise indicated herein.If your company can provide the product/services listed on the solicitation and comply with all of the solicitation instructions, please respond to this notice. To view the specifications, please go to www.FedBid.com and reference Buy No. 274960_01. GSA Schedule Bids Only: Sellers bidding on this opportunity MUST have the items requested on an existing GSA Schedule. The Schedule must either be in the Seller's name or the Seller must be able to document its ability to act as an agent of a partner's Schedule. Sellers must not bid more than their applicable contract ceiling price, excluding the FedBid Fee, for contract-specific items. If FedBid receives notice that, due to inclusion of the FedBid Fee, the Selected Bid's line item pricing is higher than the Selected Seller's applicable published government contract pricing, the FedBid Fee will be reduced to ensure the Selected Bid's line item pricing does not exceed the Selected Seller's applicable contract pricing. Sellers may offer Open Market items only in accordance with the approved Terms and Conditions of their respective GSA Schedule AND upon approval from the soliciting Contracting Officer. Information regarding GSA Schedules can be found at www.GSA.gov. This requirement is a [ Small Business ] set-aside and only qualified sellers may submit bids.The solicitation pricing on www.FedBid.com will start on the date this solicitation is posted and will end on 2011-08-22 18:00:00.0 Eastern Time or as otherwise displayed at www.FedBid.com.FOB Destination shall be Chamblee, GA 30341 The Centers for Disease Control & Prevention requires the following items, Meet or Exceed, to the following: LI 001, MSIA development: The objective is to incorporate the existing anti-ricin antibody used by the CDC with I13I's MSIA tips and to determine their ability to detect ricin spiked into buffer and complex media, i.e. milk and/or fruit juice. Investigations will begin with examining assay parameters (i.e. amount of antibody, sample size, buffer compatibility, etc.) to determine those that provide the lowest limit-of?detection (LOD) for ricin spiked samples (buffer, milk and/or fruit juice spiked with ricin). An LOD in the femtomole (10-15) range will be our target, as this is the LOD currently obtainable via CDC's ricin LC-MS assay. As it is known from CDC's current studies involving the anti-ricin antibody, which is to be supplied for these studies, cross-reactivity with agglutinin (a known protein component common in ricin preparations with shared sequence homology with ricin) and with RCA 1 20 (a sister protein to ricin, sharing sequence homology with ricin) are anticipated. Due to the sequence homology within these three proteins and the presence of heterogeneous glycosylation within each protein, it is projected that methods of deglycosylation and/or digestion may be required for the explicit detection of ricin. Therefore, the provide quote includes anticipated costs of the necessary reagents for these steps.Although the assays LOD is of importance, the CDC has indicated to IBI that the assays ability to quickly detect ricin from prepared samples is of greater importance. The current ricin assay used by the CDC requires an extensive amount of time to perform, due to time required for trypsin digestion of the immunoaffinity captured ricin and the performance of LC prior MS detection. Furthermore, the ability to analyze large numbers of samples in a timely manner is impeded by the limitation of the LC-MS method's analysis rate (10 - 30 minutes per single analysis). Using I13I's MSIA technology, one is able to significantly increase the sample throughput. I13I's MSIA tips are compatible with pipetting workstations, enabling 96 samples to be processed in parallel (~1 hr from sample preparation to data acquisition) and therefore allowing the analyses of several hundred samples to be performed within a single day. In addition, MSIA technology enables the detection of full length proteins (using Matrix-Assisted Laser Desorption/Ionization time-of-flight (MALDI-TOF) mass spectrometry) allowing for the tryptic digestion step within the current ricin assay performed by the CDC to be eliminated. This will significantly reduce the required analysis time for detecting ricin from media. In the event that digestion is required for ricin's explicit detection, I13I has additional technology (in the form of Bioreactive Probes, BRPs) and knowhow to perform digestions more efficiently and more quickly, reducing analysis time and reagent consumption. The significant reduction in analysis time and increase in throughput for the detection of ricin will translate into faster responses to environmental hazards., 1, EA; LI 002, Quantitative development: The objective here is to make the developed ricin MSIA from Objective 1 quantitative by incorporating an internal reference that will be co-extracted and detected by the developed Ricin MSIA. Quantification by MSIA requires the incorporation of an internal reference into the protocol to normalize events within the immunoaffinity purification and the MS detection of ricin. Through the use of an internal reference, a standard curve (a plot of known concentrations of ricin versus the ratio between signals of ricin and the internal reference) will be generated to enable the quantity of ricin in each analyzed sample to be determined. Efforts will be begin with identifying a suitable internal reference that contains the following characteristics: 1) has sequence homology with ricin to enable its co-extraction with ricin by the anti-ricin antibody, 2) has a different mass than that of ricin to enable its signal to be resolved in the mass spectrum from that of the signal from ricin, and 3) can be provided in a pure form of known concentration. A suitable internal reference could be a form of ricin that is shifted higher in mass by a label (biotin, his-tag, isotopic labeling) or by production of a recombinant ricin containing a slight sequence modification. At this time the CDC is putting forth efforts to create an isotope enriched recombinant ricin for their current assay. The production of the recombinant ricin requires that the active sight of the ricin be modified in such a manor to eliminate or at least reduce the toxin activity. This modification will likely result in a recombinant ricin that is different in mass to that of ricin expressed by castor beans and may be a suitable internal reference for the developed ricin MSIA. Once a suitable internal reference is identified, the quantitative ricin MSIA will be tested for its limit of quantification (LOQ). Adjustments in the assay's protocol may be warranted at this time to improve the assays LOQ. The goal is to have a LOQ within the picomole range., 1, EA; LI 003, Validation of Ricin MSIA: The goal of this objective is to validate the developed Ricin MSIA and optimize its performance for high reproducibility. We will follow analytical approaches to optimize highly reproducible Ricin MSIA suited for high throughput application. The quantitative aspect of the assay will be optimized for dynamic range, LOQ, and LOD. Coefficients of variation (CV) at suspected analytical concentrations (or standard error of working curve) will be monitored for intra- and inter-day and adjustments will be made, if necessary, to provide intra- and inter-CVs of < 15%., 1, EA; Solicitation and Buy Attachments ***Question Submission: Interested offerors must submit any questions concerning the solicitation at the earliest time possible to enable the Buyer to respond. Questions must be submitted by using the 'Submit a Question' feature at www.fedbid.com. Questions not received within a reasonable time prior to close of the solicitation may not be considered.*** For this solicitation, Centers for Disease Control & Prevention intends to conduct an online competitive reverse auction to be facilitated by the third-party reverse auction provider, FedBid, Inc. FedBid has developed an online, anonymous, browser based application to conduct the reverse auction. A Seller may submit a series of pricing bids, which descend in price during the specified period of time for the aforementioned reverse auction. Centers for Disease Control & Prevention is taking this action in an effort to improve both seller access and awareness of requests and the agency's ability to gather multiple, completed, real-time bids.All responsible Sellers that respond to this solicitation MUST submit the pricing portion of their bid using the online exchange located at www.FedBid.com. There is no cost to register, review procurement data or make a bid on www.FedBid.com.Sellers that are not currently registered to use www.FedBid.com should proceed to www.FedBid.com to complete their free registration. Sellers that require special considerations or assistance may contact the FedBid Helpdesk at 877-9FEDBID (877-933-3243) or via email at clientservices@fedbid.com. Sellers may not artificially manipulate the price of a transaction on www.FedBid.com by any means. It is unacceptable to place bad faith bids, to use decoys in the www.FedBid.com process or to collude with the intent or effect of hampering the competitive www.FedBid.com process.Should Sellers require additional clarification, contact FedBid at 877-9FEDBID (877-933-3243) or clientservices@fedbid.com. Use of FedBid: Buyers and Sellers agree to conduct this transaction through FedBid in compliance with the FedBid Terms of Use. Failure to comply with the below terms and conditions may result in offer being determined as non-responsive. New Equipment ONLY; NO remanufactured or "gray market" items. All items must be covered by the manufacturer's warranty. Bid MUST be good for 30 calendar days after close of Buy. Shipping must be free on board (FOB) destination CONUS (Continental U.S.), which means that the seller must deliver the goods on its conveyance at the destination specified by the buyer, and the seller is responsible for the cost of shipping and risk of loss prior to actual delivery at the specified destination. Offeror must be registered in the Central Contractor Registration (CCR) database before an award can be made to them. If the offeror is not registered in the CCR, it may do so through the CCR website at http://www.ccr.gov. No partial shipments are permitted unless specifically authorized at the time of award. The National Center for Environmental Health, Program of the Centers for Disease Control and Prevention intends to award a sole source, firm fixed price contract, in accordance with FAR 13, using simplified acquisition procedures, to Intrinsic Bioprobes, Inc, 2155 E. Confederate Drive, # 104, Tempe, AZ 85284. Intrinsic Bioprobes, Inc will deliver MSIA development, Quantitative Development, and Validation of Ricin MSIA. No Request for Quotes (RFQ) will be issued based upon this Notice of Intent. This advertisement ends in 3 days accordance with FAR 5.203 (A) (1). Any interested companies are welcome to submit their ability to provide these samples via e-mail, efi6@cdc.gov. Please include reference number (2011-01673). Please respond by Wednesday, August 10, 2011.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/01673/listing.html)
- Place of Performance
- Address: Chamblee, GA 30341
- Zip Code: 30341
- Zip Code: 30341
- Record
- SN02542442-W 20110821/110819235931-f75adb9f97bd1c67196a36680d788561 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |